|
The Biotechnology Innovation Organization (BIO) got its start through a need to come together to create one voice for a fledgling industry. So much has happened in 25 years. Watch the video to learn more.Continue reading
Megha Padi, PhD, harnesses the computational power of bioinformatics to learn more about cancer and how best to treat it — and empowers other cancer researchers to do the same.Continue reading
INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance clinical research of dronabinol inhalation using a novel and patented breath-actuated device—licensed from U.K.-based Senzer Ltd. and accepted by the U.S. Food and Drug Administration (FDA) under an investigational new drug (IND) filing—in the second half of 2018.
Continue reading
Collaboration will accelerate patient access to clinical trials through advanced predictive modeling tools and patient screening technologies
Mr. Lubniewski assumes the role after having served for seven years as Chief Business OfficerContinue reading
RightBio Metrics announced its RightSpotpH® indicator has received an innovative technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country.Continue reading
VisionGate Reports Important New Research at the 2018 AACR Annual Meeting on how its Cell-CT™ platform can detect subtle changes in cellular and nuclear morphology of cancer-associated cells (CACs) as a result of the cancer field effect. Continue reading
A new company designed to more efficiently and effectively deliver select natural ingredients for use in personal care, cosmetic, nutraceutical, and pharmaceutical industries.Continue reading
Tucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path Institute (C-Path) a grant to support a Crohn’s disease biomarker pre-consortium. The pre-consortium will identify unmet needs for the use of biomarkers in developing new treatments for people with Crohn’s disease.Continue reading